Skip to main content
Equibles

4553 · TOWA PHARMACEUTICAL CO.,LTD. · Financials

Use 4553 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4553.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,460 JPY -45 (-1.28%) At close · Nov 11
Rebalance outlook locked
Market Cap
170.33B JPY
Shares
49.23M
Volume · Nov 11 178.9K Avg daily vol (3M) 120.88K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
273.71B +5.4%
FY2026 Revenue FY2022–FY2026
Net Income
5.25B -72.3%
FY2026 Net Income FY2022–FY2026
Gross Margin
36.21% -0.3pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
8.44% -0.5pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
30.43B +30%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 273.71B 259.59B 227.93B 208.86B 165.62B
JPY 174.61B 164.87B 146.55B 136.15B 95.43B
JPY 99.1B 94.73B 81.38B 72.71B 70.19B
JPY 23.1B 23.24B 17.65B 5.51B 19.21B
JPY 13.17B 26.33B 24.46B 4.61B 22.25B
JPY 7.91B 7.34B 8.29B 2.4B 6.33B
JPY 5.25B 18.99B 16.17B 2.2B 15.91B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 15.35B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.